Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Compass Group on the acquisition of Fazer Food Services from Fazer Group
Mandate

Vinge advises Compass Group on the acquisition of Fazer Food Services from Fazer Group

June 11, 2019 M&A

Fazer Food Services is a renowned food catering business in the Nordic region with operations in Finland, Sweden, Norway and Denmark, across several sectors including Business & Industry, Education, Healthcare, Seniors and Defence. with an enterprise value of approximately €475 million.

Vinge’s team consists of responsible partners Christina Kokko and Matthias Pannier as well as senior associate Anna Thoms, together with partner Daniel Rosvall, associates Fredric Reissmüller, Hampus Olsson, Christina Odengran and Marcus Eklund (M&A), Fredrika Hjelmberg (IT/Commercial Agreements), Klara Secher (IP), Maria Schultzberg, Henrik Wastenson (Tax), Lova Unge (Employment), Daniel Wendelsson (Public Procurement) and Veronika Garemark (Real Estate). 
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024